The practice of bailing out insurance companies in response to policy mistakes undermines the effective management of the health care system. The decision to end a key subsidy program reflects this challenge.

The subsidy in question supported stand-alone plans within Medicare Part D, specifically targeting the prescription drug benefit for seniors. This subsidy acted more as a short-term remedy rather than addressing the overarching health care cost issues.

A recent announcement from the Trump administration confirmed that the program will conclude this year, earlier than initially planned. Originally set to extend until 2027, the program’s abrupt end raises questions about future strategies for managing prescription drug costs effectively.